Identity
Laboratorios Normon, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €1.66M | |
| 2025 | €2.73M | |
| 2024 | €2.41M | |
| + regional platforms | ||
| 2023 | €2.52M | |
| 2022 | €1.47M | |
| 2021 | €3.30M | |
| 2020 | €0.62M | |
| 2019 | €0.88M | |
| 2018 | €0.16M | |
| 2017 | €0.10M | |
| 2016 | €0.23M | |
In figures
Volume
Between 2016 and 2026 it won 845 contracts worth €16.1M on its own, with 30 buyers. Its 7 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 20.5%; the middle half of its discounts between 8.5% and 32.3% (33 comparable awards).
Competition
Since 2024, 47% of its comparable value was won with a discount and against other bidders. It was the only bidder in 78% of its contracts (2016–2026).
Renewals
57 contracts (€2.03M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Laboratorios Normon, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Laboratorios Normon, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 20.5% · middle half between 8.5% and 32.3% · 33 awards
2018–2023: median 17.3% (45 awards) · 2024–2026: median 20.5% (33 awards).
2018–2026: median 17.5% · middle half between 7.2% and 34.6% · 78 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Productos farmacéuticos
CPV 336
356 contracts · €6.80M
By buyer · 2024–2026
Dirección Gerencia del Complejo Hospitalario Universitario Insular Materno Infantil
Productos farmacéuticos
227 contracts · €2.34M
Servicio Murciano de Salud - Junta de Compras
Productos farmacéuticos
12 contracts · €1.18M
Servicio de Salud - Servicios Centrales
Productos farmacéuticos
2 contracts · €396k
Dirección General de Planificación Económica
Productos farmacéuticos
7 contracts · €275k
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
24 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
47% of the comparable value since 2024 (€1.27M of €2.72M) was won with a discount and against other bidders. €856k (32%) was awarded with a discount and without other bidders.
Comparable: 72 awards with a published budget and bidder count (€2.72M of €6.80M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 61.8% of the value was awarded through open procedure (51.8% of contracts); followed by Based on a framework agreement (30.6%) and Negotiated without publicity (4.1%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 57 of its contracts come up for tender again, worth €2.03M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Servicio de Salud - Servicios Centrales | €160k |
| 2026 | OSAKIDETZA - Servicio Vasco de Salud -Director General | €79.2k |
| 2027 | OSAKIDETZA - Servicio Vasco de Salud -Director General | €24.0k |
| 2027 | Gerencia Asistencial de Atención Primaria | €20.5k |
| 2027 | Gerencia Sector Sanitario de Zaragoza 2 | €2.64k |
and 52 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Gerencia de Servicio Sanitarios de Fuerteventura | 496 | 7.4 M | 2019–2026 |
| Servicio Murciano de Salud - Junta de Compras | 21 | 2.3 M | 2022–2026 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 27 | 1.3 M | 2024–2026 |
| Servicio de Salud - Servicios Centrales | 10 | 952 k | 2021–2026 |
| Gerencia de Atención Integrada de Talavera de la Reina | 83 | 567 k | 2018–2025 |
and 25 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 843 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 18/06/2026 | Medicamentos con destino a los Centros de Atención Primaria del Servicio Madrileño de Salud | Gerencia Asistencial de Atención Primaria | 1 | €8.04k |
| 04/11/2025 | Suministro de Omeprazol (DOE), Temozolomida (DOE), Teicoplanina (DOE) y Folinato cálcico (DOE) | OSAKIDETZA - Servicio Vasco de Salud -Director General | 2 | €79.2k |
| 11/09/2025 | cbam_laboratorioa normon, s.a. -acuerdo marco con una unica empresa para el suministro, de tracto s… | Servicio Andaluz de Salud | 1 | €16.0k |
| 11/08/2025 | Suministro de Sildenafilo (DOE), Ibuprofeno (DOE), Fenilefrina (DOE) Y Caspofungina (DOE) | OSAKIDETZA - Servicio Vasco de Salud -Director General | 1 | €7.00k |
| 08/08/2025 | Suministro lote 195 del acuerdo marco para el suministro de medicamentos de uso humano tipo I, incl… | Dirección Gerencia del Complejo Hospitalario Universitario de Canarias | 1 | €4.77k |